Damora Therapeutics, Inc. DMRA
Super Investor & Insider
1
Fondi che lo detengono
#841
Rank consenso
1.4%
% dei portafogli
$59.9M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Viking Global Investors · Viking Global Investors | 0.17% | Buy | 2,311,082 | $59.9M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Damora Therapeutics, Inc. is a clinical-stage biotechnology company developing small molecule therapeutics targeting fibrosis, cancer, inflammation, and related diseases. Its lead candidates include GB3226, a preclinical dual inhibitor of ENL-YEATS and FLT3 aimed at blood cancer indications such as acute myeloid leukem…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees7
TickerDMRA
Statistics
Market Cap$1.27B
Revenue (TTM)—
Net Income-$209.8M
Net Margin—
EPS$3.98
P/E-5.20
P/S—
P/B3.48
EV/EBITDA-14.12
ROE-89.5%
Dividend Yield—
Price$20.98
Data: Twelve Data · Revenue = mcap / P/S